Prof. Ravi Thadhani M.D., M.P.H.
Harvard Medical School
Ravi Thadhani, M.D., M.P.H. is a Professor of Medicine at Harvard Medical School, Chief of the Division of Nephrology at Massachusetts General Hospital, and Executive Director of the Clinical Trials Office at Partners Health Care. He received his Doctor of Medicine degree from the University of Pennsylvania in 1991, and, in 1997, received his Masters in Public Health in Epidemiology from the Harvard School of Public Health.

He is a clinical and translational investigator and, over the past 16 years, his research laboratory has focused on developing diagnostics and therapeutics related to preeclampsia, and understanding vitamin D metabolism. His priority is to have a positive impact on clinical practice and improve outcomes. Prof. Thadhani and his collaborators have developed novel diagnostic tests for preeclampsia, and are now arduously working on therapies to safely prolong pregnancy in women with very severe preterm preeclampsia. He is actively performing first-in-human randomized trials based on extensive pilot studies (Circulation 2011 and the Journal of the American Society of Nephrology 2015).

His pregnancy studies center on human research supporting recent findings emerging from basic science collaborations in the area of angiogenic factors and preeclampsia. He has performed pilot and proof-of-concept studies, retrospective and prospective (>10,000 women, > 30,000 blood samples) studies, and planned and performed interventional trials. A diagnostic test he and his team developed is currently in the clinic in Europe. He has several grants, invited speaking events, book chapters, and publications in this area, including invited commentaries.


Title: Potential Therapeutics In Pre-Eclampsia

Over the past two decade our understanding of the pathophysiology of preeclampsia has considerably improved. Despite these advances, no specific therapy for preeclampsia has been developed. In this presentation, we will briefly review the experimental and clinical evidence suggesting sFlt-1 could be a target for therapies to prevent or treat preeclampsia. More importantly we will discuss the challenges and emerging opportunities in developing a therapy to prolong
pregnancy in women with severe preterm preeclampsia.